Recruiting

N/A

39

Japan

Amnolake (tamibarotene) - Syros, Nippon Shinyaku, Zeria Pharma, RaQualia, Ohara Pharma, arsenic trioxide - Generic mfg., Mylotarg (gemtuzumab ozogamicin) - UCB, PDL, Pfizer

Dokkyo Medical University Saitama Medical Center

Relapsed acute promyelocytic leukemia

 

 

Completed

N/A

60

 

1. ATAR plus ATO: Oral administration of ATRA (45mg/d), plus intravenous injection of arsenic trioxide (0.16mg/kg/d), till achievement of morphological complete remission (not less than 28 days); 2. ATAR plus ATO: Oral administration of ATRA (45mg/d), plus intravenous injection of arsenic trioxide (0.16mg/kg/d), for 28 ;4. ATAR plus ATO: Oral administration of ATRA (45mg/d), plus intravenous injection of arsenic trioxide (0.16mg/kg/d), for 28 days; 5. DA regimen: intravenous injection of Daunorubicin (45mg/m2/day) for 3 days plus cytarabine (200mg/day) for 7 days; 6. ATAR plus ATO: Oral administration of ATRA (45mg/d), plus intrav ;7. MA regimen: intravenous injection of Mitoxanetrone (10mg/day) for 3 days plus cytarabine (200mg/day) for 7 days; 8. ATAR plus ATO: Oral administration of ATRA (45mg/d), plus intravenous injection of arsenic trioxide (0.16mg/kg/d), for 28 days; 9. ATAR plus ATO: Oral administration of ATRA (45mg/d), plus intraven ;10. ATAR plus ATO: Oral administration of ATRA (45mg/d), plus intravenous injection of arsenic trioxide (0.16mg/kg/d), for 28 days; 11. Prophylaxis of central nervous system leukemia (CNS-L): intrathecal injection with 5mg dexamethasone plus 15mg MTX for 6 times totally after achievement of CR.

大连医科大学附属第二医院血液科; Level of the institution：, LiaoNing Project for Medicine Peak Construction (No.201112;2011-2013). 200,000 Yuan.

Acute Promyelocytic Leukemia

 

 

Completed

N/A

347

NA

consolidation with ASCT, consoliation therapy

Huazhong University of Science and Technology, Peking University People's Hospital, Ruijin Hospital, West China Hospital

T-cell Lymphoma Adults

01/22

07/23

Recruiting

N/A

240

 

in vitro culture ;cytarabine ;Adriamycin ;Daunorubicin

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Blood Diseases Hospital & Chinese Academy of Medical Sciences, Chinese National Natural Science Foundation

Acute myeloid leukemia

 

 

Recruiting

N/A

4000

RoW

Dexamethasone continuous, Dexamethasone intermittent, Dexamethasone, Methylprednisolone, Daunorubicin, Idarubicin, Bortezomib, Second phase of induction, Standard induction therapy, Standard consolidation therapy

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Childhood Acute Lymphoblastic Leukemia

11/20

11/25

Recruiting

N/A

60

 

G-csf priming and cladribine plus cytarabine included conditioning regimen ;traditional condition regimen

Xin Qiao hospital; Xinqiao hospital, self-raise

Acute leukemia

 

 

Recruiting

N/A

220

 

CEAC+Cla ;CEAC

The Second Affiliated Hospital of Army Medical University; xinqiao hospital, National Nature Science Fund 81370594，National Nature Science Fund 81670100

lymphoma

 

 

Recruiting

N/A

200

Europe

IDARUBICINE, ARA-C

PETHEMA Foundation

Acute Myeloblastic Leukemia

12/21

12/21

Recruiting

N/A

20

RoW

rhTPO, Decitabine, Aclarubicin, G-CSF, Cytarabine

Huihan Wang

Acute Myeloid Leukemia

12/21

12/24

Recruiting

N/A

500

RoW

Interni hematologicka klinika FNKV, Charles University, Czech Republic, General University Hospital, Prague, University Hospital Olomouc, University Hospital Hradec Kralove, University Hospital, Motol

Prognostic Cancer Model

12/23

12/27

Completed

N/A

40

 

None

Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, Shanghai Shenkang Clinical Innovation Project (SHDC12020112)

primary central nervous system lymphoma

 

 

Recruiting

N/A

58

 

Etoposide 60mg/m2/d d1-4; Methylprednisolone 500mg/d d1-4; Cytarabine 2g/m2/Q12h d5; Cisplatin 25mg/m2/d d1-4 ;Etoposide 60mg/m2/d d1-4; Methylprednisolone 500mg/d d1-4; Cytarabine 2g/m2/Q12h d5; Cisplatin 25mg/m2/d d1-4; ATO 10mg/d d1-14

Tongji Hospital Affiliated to Tongji University School of Medicine; Tongji Hospital Affiliated to Tongji University School of Medicine, Shanghai Municipal Health Planning Commission clinical research fund project

ALK+ anaplastic large cell lymphoma

 

 

Recruiting

N/A

76

 

Prophylaxis after chemotherapy ;Prophylaxis before chemotherapy

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Wuhan Central Hosptial, self-raised

Acut Myloid Leukima

 

 

Recruiting

N/A

15

Europe

parent-led home-administered low-dose Cytarabine

Rigshospitalet, Denmark

Supportive Care, Childhood Cancer

12/22

02/23

Recruiting

N/A

200

 

Cytarabine at 1g or 2g

The First Affiliated Hospital of Soochow University; Beijing Medical Award Foundation, Beijing Medical Award Foundation

Relapses of refractory acute myeloid leukemia

 

 

Recruiting

N/A

2500

Europe

Acute Leukemia French Association

Acute Myeloid Leukemia (AML)

04/32

04/46

Not yet recruiting

N/A

65

 

HYPER-B program

Peking University, People's Hospital, Peking University Institute of Hematology; Peking University, People's Hospital, self-raised

Refractory and Relapse Acute Myeloid Leukemia

 

 

Not yet recruiting

N/A

536

 

Based on an accurate risk stratification system including the levels of plasma cfBRAF-V600E, LCH patients were treated by the first-line therapy (Prednisone, Vindesine), the second-line therapy (Cladribine and/or Cytarabine) and/or targeted therapy (Dabrafenib) and the maintenance therapy (Vindesine, Prednisone, 6-Mercaptopurine). ;According to the conventional evaluation system of involved organs, LCH patients were treated by the first-line therapy, the second-line therapy and the maintenance therapy.

Beijing Children's Hospital, Capital Medical University, National Children's Medical Center; Beijing Children's Hospital, Capital Medical University, National Children's Medical Center, the Capital Health Research and Development of Special Grant

Langerhans cell histiocytosis

 

 

Not yet recruiting

N/A

42

 

Azacitidine Combined with Low-Dose Cytarabine regimen

The First Affiliated Hospital, College of Medicine, Zhejiang University; The First Affiliated Hospital, College of Medicine, Zhejiang University, No sources

Acute myeloid leukemia

 

 

Recruiting

N/A

60

RoW

dasatinib plus consolidation chemotherapy with vincristine and prednisone, Dasatinib + VP Regimen, dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine, Dasatinib + HyperB Regimen

First Affiliated Hospital Xi'an Jiaotong University

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia-Positive Acute Lymphoblastic Leukemia, ALL, Adult

06/23

06/23

Completed

N/A

60

RoW

BEAM Protocol, (Bendamustine, Etoposide, Cytarabine, Melphalan, CEM protocol, (Carboplatin, Etoposide, Melphalan)

Rehab Werida

Lymphoma

09/23

12/23

Recruiting

N/A

210

 

1.Pretreatment: If patients with WBC ≥ 30000/L or with severe hepatosplenomegaly or lymph node enlargement then should receive Prednisone 1 mg/kg/d, 3-5 days, or the same amount of Dexamethasone ;2.Induction regimen (4-week FVD regimen): Flumatinib(FM) 600mg Po Qd+ Vindesine(VDS) 4mg/d (D1, 8, 15, 22) + Dexamethasone(DXMS) 20mg/d (D1-4, 8-11, 15-18, 22-25) (bone marrow aspiration and detection of BCR/ABL copies on the 14th and 28th day) ;3. Consolidation therapy (8 weeks, divided into two stages, each stage 4 weeks). CAM regimen [Cyclophosphamide(CTX) 1000mg/m2/d (d1) + Cytarabine(Ara-C) 75 mg/m2/d (d3-6,10-13) + 6-Mercaptopurine(6-MP) 60mg/m2/d Po (d1-14)].F-CAM regimen [FM 600mg mg/m2/d (d1) + CTX 750 mg/m2/d (d1) + Ara-C 75mg/m2/d (d3-6,10-13) + 6-MP 60 ;4.Intensive therapy (1-2 times): Hyper-CVAD-B regimen: MTX 1g/m2 was infused continuously for 24 hours, and Calcium Folinate was given for detoxification per 12 hours. After detoxification, Ara-C 3mg / m2 was given intravenously for 4 times every 12 hours. (if the symptoms of oral mucosal erosion, ulcer and ;5.Transplantation: If the minimal residual disease (MRD) of fusion gene is persistent negative, then autologous hematopoietic stem cell transplantation would be selected (ASCT); otherwise allogeneic hematopoietic stem cell transplantation (allo-HSCT) would be. ;6.Maintenance therapy: allo-HSCT: FM 600mg/d lasts for 1 year;ASCT: FVP regimen 28 days/course, lasting for one year: FM 600mg+VDS 4mg (d1)+Prednisone 1mg/kg/d (d1-5). ;7.Whole course prophylaxis of central nervous system leukemia(CNSL) : Intrathecal injection (MTX 10 mg + Ara-C 50 mg + DXM 10 mg) was performed at least 12-16 times, and patients intending to undergo SCT should complete 4-6 times before SCT.

Department of Hematology, The First Affiliated Hospital of Chongqing Medical University; Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Self-raised

Acute lymphoblastic leukemia with Ph-positive

 

 

Not yet recruiting

N/A

150

NA

Vincristine, Dexamethasone, Imatinib, Cytarabine, Mercaptopurine, Methotrexate, Ponatinib, allogeneic stem cell transplantation, Total body irradiation, Cyclophosphamide, Fludarabine

PETHEMA Foundation

Lymphoblastic Leukemia, Philadelphia-Positive ALL, Adult ALL

12/28

12/30

Recruiting

N/A

54

RoW

Venetoclax : 100mg on day 1, 200mg on day 2, 400mg on days 3 to 8; oral administration;, Idarubicin (Idarubicin): 10-12mg/m2 on days 1 to 3; intravenous infusion, ;Cytarabine (Cytarabine): 100mg/m2 on days 1 to 7; intravenous infusion or subcutaneous injection., Venetoclax (Venetoclax): 400mg on day 1 to day 7; oral administration;, Cytarabine: 2g/m2 every 12 hours on day 1 to day 3; intravenous infusion;, utologous stem cell transplantation (ASCT) /allogeneic hematopoietic stem cell transplantation (allo-HSCT).

The First Affiliated Hospital with Nanjing Medical University, Huai'an First People's Hospital, Yancheng First People's Hospital

Acute Myeloid Leukemia

12/27

12/27

Not yet recruiting

N/A

40

NA

Azacitidine Injection, Azacitidine

Wuhan Union Hospital, China

Myelodysplastic Syndromes

01/26

01/26

Recruiting

N/A

30

 

Azacitidine+Venecla+Medium-dose Cytarabine+Microtransplantation ;Azacitidine+Venecla+Microtransplantation ;Azacitidine+Venecla

Ningbo First Hospital; Ningbo First Hospital, None

Acute myeloid leukemia (AML)

 

 

Not yet recruiting

N/A

34

 

EAP regimen

The Affiliated People's Hospital of Ningbo University ; The Affiliated People's Hospital of Ningbo University, None

hematological malignancies

 

 

Recruiting

N/A

20

 

According to the classification, ATG + CsA/CSA alone is used as the pretreatment plan/supportive treatment + non-blood cord blood stem cell infusion treatment ;Decitabine+cytarabine/decitabine alone is used as the pretreatment plan/supportive treatment+non-blood cord blood stem cell infusion treatment according to the classification

The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital); The Second Affiliated Hospital Of Xi'an Jiaotong University (Xibei Hospital), None

myelodysplastic syndromes/aplastic anemi

 

 

Not yet recruiting

N/A

90

RoW

Allogeneic Hematopoietic Stem Cell Transplantation, Chemotherapy, High-dose cytarabine

Ruijin Hospital

Acute Myeloid Leukemia

09/25

02/28

Not yet recruiting

N/A

20

RoW

Selinexor, Homoharringtonine, Cytarabine, Aclacinomycin, Granulocyte Colony-Stimulating Factor, Decitabine, Azacitidine

The First Affiliated Hospital of Soochow University

Relapsed/Refractory AML

06/24

06/24

Recruiting

N/A

36

RoW

cladribine, cytarabine,venetoclax

The First Affiliated Hospital of Soochow University, Jining Medical University, The Second People's Hospital of Huai'an, First Affiliated Hospital Bengbu Medical College, Northern Jiangsu People's Hospital, Affiliated Hospital of Nantong University, Suzhou Hospital of Traditional Chinese Medicine

Acute Lymphoblastic Leukemia

10/24

10/24

Not yet recruiting

N/A

52

NA

Venetoclax, Carmustine, Cytarabine, Etoposide, Melphalan, Hematopoietic Cell Transplantation

Ruijin Hospital

Diffuse Large B Cell Lymphoma

11/24

11/25

Not yet recruiting

N/A

20

NA

Autologous haemopoietic stem cell transplantation

Tianjin Medical University General Hospital

Multiple Sclerosis

01/29

01/29

Recruiting

N/A

300

RoW

ATG, Post-transplantation cyclophosphamide

Peking University People's Hospital, Sanofi

Hematological Malignancy

07/25

12/25

Not yet recruiting

N/A

110

 

Mefalun+cyclophosphamide+CLAD+Ara-C (MCAC) ;TBI+CLAD+Ara-C (TCAC)

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, drugs

ALL

 

 

Not yet recruiting

N/A

50

RoW

TBF regimen, Conditioning treatment with TBF regimen, modified BuCY2 regimen, Conditioning treatment with modified BuCY2 regimen

First Affiliated Hospital Xi'an Jiaotong University

Central Nervous System Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation

12/25

12/25

Recruiting

N/A

90

RoW

Mitoxantrone hydrochloride liposome injection30mg/m2, HomoharringtonineD1-D7(2mg/m2/day), Venetoclax (d4 100mg/day, d5200mg/day ,d6-d12 400mg/day), Cytarabine(standard-dose:d1-d7100mg/m2/day), Cytarabine(intermediate-dose:d1-d4100mg/m2/day, d5-d7 1g/m2), Mitoxantrone hydrochloride liposome injection24mg/m2

Institute of Hematology & Blood Diseases Hospital, China

Acute Myeloid Leukemia

10/26

12/26

Not yet recruiting

N/A

53

RoW

Improved BEAM regimen, Conditioning treatment with improved BEAM regimen

First Affiliated Hospital Xi'an Jiaotong University

Lymphoma, Autologous Hematopoietic Stem Cell Transplantation

12/26

12/26

Recruiting

N/A

180

RoW

Prednisone, Vincristin, Daunorubicin, Peg-asparaginase, Intrathecal Suspension, Cyclophosphamide, Cytarabine, Mercaptopurine, Methotrexate, Doxorubicin

Instituto do Cancer do Estado de São Paulo, Servier

Acute Lymphoid Leukemia, Minimal Residual Disease, Gene Abnormality, Chemotherapeutic Toxicity

06/28

06/30